Years ago, I was standing at a chemist counter in a small district town, waiting to meet the owner. A young mother walked in with two prescriptions folded together. One was for her four-year-old’s fever and cough. The other was for her father’s diabetes and blood pressure.
Same family. Same bill. Same counter. Two completely different doctors.
The chemist had the child’s syrup. He did not have the grandfather’s combination tablet, so she walked out to try another shop. I remember thinking: whoever stocks both of these, reliably, owns this family for the next twenty years.
That moment shaped how I have built and advised PCD businesses ever since. And it is the whole idea behind this guide.
What Is a Pediatric and Cardiac Diabetic PCD Pharma Franchise?
A Pediatric PCD Pharma Franchise is a business model where a pharma company gives you the right to market and distribute its children’s medicines (syrups, dry syrups, drops, suspensions, sachets) in a defined territory, under the company’s brand, with you handling promotion and sales. PCD stands for Propaganda Cum Distribution.
A Cardiac Diabetic PCD Pharma Franchise works the same way, but the range covers chronic medicines for diabetes, hypertension, cholesterol and heart care.
A dedicated dual-segment franchise combines both under one partnership. You get one supplier, one agreement and one set of monopoly rights, but two very different prescription engines.
Here is how I explain the difference to every new partner who sits across my desk:
| Factor | Pediatric segment | Cardiac Diabetic segment |
|---|---|---|
| Prescribers | Pediatricians, general physicians, family doctors | Physicians, diabetologists, cardiologists, endocrinologists |
| Nature of demand | Acute, seasonal, high volume | Chronic, monthly refills, very predictable |
| Typical dosage forms | Syrups, dry syrups, drops, suspensions | Tablets, combination tablets, capsules |
| Repeat purchase | Every illness episode | Every month, often for life |
| Cash flow pattern | Spikes during monsoon and winter | Steady all year |
| Biggest risk | Taste and quality complaints from parents | Doctors switching brands if supply breaks |
Read that table again, slowly. One segment gives you volume and fast rotation. The other gives you stability. That is the entire business case in six rows.
Why Combine Pediatric and Cardiac Diabetic PCD Pharma Franchise Segments?
Pairing these two segments gives you the two largest and most dependable patient pools in India: children, who fall sick often, and adults with chronic metabolic disease, who need medicine every single month.
I did not arrive at this from a spreadsheet. I arrived at it after watching too many distributors build a business on one segment and then struggle through its off-season. The data simply confirmed what the market had already taught me.
The cardiac diabetic side:
- India had an estimated 101 million people with diabetes and 136 million with prediabetes in 2021, according to the ICMR-INDIAB study published in The Lancet Diabetes & Endocrinology (2023). (ThePrint)
- The same study estimated 315 million people with high blood pressure and 213 million with high cholesterol. (M3 India)
- The number of people with diabetes grew 44% from about 70 million in 2019, per the same study. (Scroll)
The pediatric side:
- Children aged 0 to 14 make up 24% of India’s population, according to UNFPA’s State of World Population 2025 report. (Drishti IAS summary)
- With India’s population estimated at about 146 crore in April 2025, that is roughly 35 crore children. (UNFPA)
Now put those together the way a field person sees them. Diabetic patients rarely take one molecule. Most end up on a diabetes combination, a statin and a blood pressure tablet. That is three or four products per patient, refilled every month. This kind of recurring demand is what makes a PCD pharma franchise opportunity worth building.
Children, on the other hand, bring you volume in waves. Monsoon fevers, winter coughs, summer diarrhoea. A good pediatric range keeps your stockists busy and your cash moving.
In plain terms: pediatric products pay your monthly bills, and cardiac diabetic medicines build the long-term value of your business.
Investment Required for a Pediatric PCD Pharma Franchise and Cardiac Diabetic PCD Franchise
In my experience, a single-segment Pediatric PCD Pharma Franchise can start with roughly ₹1.5 lakh to ₹3 lakh. A dual Pediatric and Cardiac Diabetic franchise for one district usually needs ₹3 lakh to ₹7 lakh, including licence, setup, first stock and three months of working capital.
These are my working figures from setting up and advising partners across tier-2 and tier-3 markets. Your city, rent and team size will move them up or down.
| Cost head | Pediatric only (₹) | Pediatric + Cardiac Diabetic (₹) | What I tell partners |
|---|---|---|---|
| Drug licence (Form 20B + 21B) government fee | 3,000 | 3,000 | ₹1,500 per form; add consultant charges if you use one |
| Premises setup (rack, AC, shelving) | 20,000 to 50,000 | 30,000 to 60,000 | Minimum 10 sq m for wholesale |
| Refrigerator for cold storage items | 15,000 to 25,000 | 15,000 to 25,000 | Needed for probiotics and temperature-sensitive drops or suspensions |
| First stock order | 60,000 to 1,50,000 | 1,50,000 to 3,50,000 | Start with 25 to 40 fast movers, not the full catalogue |
| Working capital (3 months) | 50,000 to 1,00,000 | 1,00,000 to 2,00,000 | Covers credit to chemists and slow initial movement |
| Field expenses (travel, samples, visual aids) | 10,000 to 30,000 | 20,000 to 50,000 | Ask the company what promo material comes free |
| Approximate total | 1.5 lakh to 3.5 lakh | 3 lakh to 7 lakh |
Two things about this table matter more than the numbers.
First, never put all your money into the opening order. I have seen partners spend 80% on stock and then have nothing left for chemist credit. Their medicines sat in cartons while competitors with smaller stock but better credit terms took the market. Credit, not stock, is what protects your profit margin in year one.
Second, cardiac diabetic products turn slower in the first three months. Doctors test a new brand on a few patients before they shift. Budget for that patience.
The legal minimums come straight from the Drugs and Cosmetics Rules: wholesale premises need at least 10 square metres, or 15 square metres if you combine retail and wholesale. (Delhi Drugs Control Department) The fee is ₹1,500 per form. (Lawrbit)
How to Start a Pediatric PCD Pharma Franchise in India: 8 Steps
To launch a Pediatric PCD Pharma Franchise or a Cardiac Diabetic PCD Pharma Franchise in India, partner with a WHO-GMP certified PCD pharma company that has a deep range in both segments.
Get your wholesale drug licence and GST registration, sign a written PCD Pharma Franchise with Monopoly Rights agreement for your territory, and start with a focused order of 25 to 40 fast-moving pediatric PCD products and cardiac diabetic medicines. Then build steady prescriptions from pediatricians, physicians and diabetologists before you expand.
This is the exact sequence I walk every new partner through. Skip a step and you usually pay for it in month four.
- Map your territory before you call any company. Count the pediatricians, physicians, diabetologists and cardiologists in your district. Visit 15 to 20 chemists and ask which pediatric syrups and diabetic combinations move fastest. This list becomes your negotiation weapon.
- Register your business. Choose proprietorship, partnership or LLP, then open a current account and get your GST registration.
- Apply for your wholesale drug licence. File Form 19 with your State Drugs Control Department for licences in Form 20B and Form 21B. You need at least 10 sq m of premises, a refrigerator and a competent person (a registered pharmacist, or a qualified person with the required experience).
- Shortlist three to five companies. Use the checklist in the “How to Choose” section below. Ask each for their product list, price list, certificates and monopoly terms in writing.
- Verify, then visit. Check WHO-GMP certificates, ask for the manufacturing site’s revised Schedule M compliance, and if possible visit the plant or the warehouse. The MSME deadline for revised Schedule M was 31 December 2025, and the health ministry signalled it would not extend it further. (Business Standard)
- Sign a written agreement. It must name your exact territory, the monopoly rights, minimum order commitments, expiry return policy and dispute terms.
- Place a focused opening order. Pick 25 to 40 products that match your territory survey. Leave room in your budget for chemist credit.
- Launch doctor by doctor. Start with the 20 doctors most likely to prescribe. Visit consistently, follow the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024 on gifts and samples, and make sure every stockist has your products on the shelf before you ask for a single prescription.
Prerequisites at a glance: GST registration, Form 20B and 21B drug licence, compliant premises, a competent person, and working capital for at least three months.
Expected outcome: In my experience, a well-run dual franchise starts seeing steady repeat orders from pediatric products within two to three months, and from cardiac diabetic products within four to six months.
Pediatric PCD Products and Cardiac Diabetic Product Range
Your opening range should cover the conditions doctors in your area treat every day, not every molecule in the company’s catalogue. Below is the core basket I recommend new partners start from. Final selection should follow your territory survey and your partner company’s approved product list.
Core Pediatric PCD Products
| Category | Common products to look for | Why it moves |
|---|---|---|
| Fever and pain | Paracetamol suspension and drops, ibuprofen suspension | Prescribed in almost every OPD visit |
| Antibiotics | Amoxicillin + clavulanic acid dry syrup, cefixime dry syrup, azithromycin suspension | High value, seasonal peaks |
| Allergy and cold | Levocetirizine syrup, montelukast + levocetirizine syrup | Year-round, strong in winter |
| Gastro care | ORS, zinc syrup, ondansetron syrup, probiotic sachets | Summer and monsoon spikes |
| Nutrition | Multivitamin drops, iron drops, vitamin D3 drops, calcium suspension | Repeat purchase for months |
Core Cardiac Diabetic Product Range
| Category | Common products to look for | Why it moves |
|---|---|---|
| Diabetes basics | Metformin (plain and SR), glimepiride + metformin | The foundation of most prescriptions |
| Newer anti-diabetics | Sitagliptin, vildagliptin, teneligliptin, dapagliflozin and their metformin combinations | Fast-growing, physician-driven |
| Hypertension | Telmisartan, amlodipine, telmisartan + amlodipine, metoprolol | Very common in diabetic patients |
| Cholesterol | Atorvastatin, rosuvastatin | Added to most cardiac diabetic prescriptions |
| Heart care | Aspirin, clopidogrel, aspirin + atorvastatin | Long-term, monthly refills |
Two hard rules from my own experience:
Check every fixed-dose combination against the latest CDSCO banned list before you order it. A banned FDC in your godown is dead money, and it damages your name with chemists.
For pediatric syrups, ask for excipient testing records. After at least 22 child deaths in Chhindwara, Madhya Pradesh, were linked to the diethylene glycol-contaminated syrup Coldrif in 2025, CDSCO asked all states in October 2026 to mandate testing of raw materials such as propylene glycol, glycerol and sorbitol, and of every finished batch. (Business Standard, The Tribune) A company that cannot show you these records should not be selling syrups to your pediatricians.
How to Choose a Cardiac Diabetic PCD Pharma Company (and the Best Pediatric PCD Pharma Company)
The best company for Pediatric and Cardiac Diabetic PCD products is the one that can prove quality, keep your shelves full and put your monopoly in writing. A glossy brochure proves none of those.
I once visited a company that had a beautiful office, a 600-product catalogue and a charming sales head. When I asked to see the stock availability for their top 30 diabetic products, a third were “coming next week.” Next week never comes in this business.
Here is the scorecard I use, whether the company runs its own plant or works with third-party pharma manufacturers. Score each company from 1 to 5 on every row.
| What to check | What good looks like | Red flag |
|---|---|---|
| Manufacturing quality | WHO-GMP certified site, revised Schedule M compliant | Refuses to share certificates or plant details |
| Range depth in both segments | 100+ pediatric products and 100+ cardiac diabetic products | Strong in one segment, token presence in the other |
| Stock availability | Top 50 products always in stock, dispatch in 2 to 5 days | Frequent “out of stock” on fast movers |
| Monopoly rights | Written district or territory exclusivity | Verbal promises only |
| Pricing and margins | Clear PTR/PTS price list with room for your margin | Prices change with every order |
| Promotional support | Visual aids, MR bags, product cards, samples | You must buy everything yourself |
| Expiry and breakage policy | Written return or replacement terms | “We’ll see case by case” |
| Pediatric syrup quality | Batch-wise excipient and finished product test records | Cannot show test records |
| Track record | Existing partners you can call | No references |
Always call at least two existing franchise partners. Ask them one question: “Has your supply ever broken for more than two weeks?” Their pause tells you more than the answer.
PCD Pharma Franchise With Monopoly Rights: What It Really Protects
Monopoly rights mean the company agrees not to appoint any other franchise partner for the same products in your territory. In a dual-segment franchise, make sure the monopoly covers both the pediatric range and the cardiac diabetic range, not just one of them.
I learned this the hard way early in my career. My agreement gave me a monopoly on “the company’s products” in a district. Six months later, the company launched a new cardiac division and handed it to someone else in my town, because technically it was a “new division.” Same doctors. Same chemists. Two people are now fighting for the same prescription.
Your monopoly clause should state:
- The exact territory (district, city or listed blocks)
- Every division and product list covered, including future launches
- Minimum order or performance conditions, if any
- The notice period and conditions under which monopoly can be withdrawn
First 90 Days of a PCD Pharma Franchise Business in India
- Days 1 to 30: Stock every chemist near your target doctors. Meet your first 20 doctors with the pediatric range, since it gets faster trial.
- Days 31 to 60: Introduce the cardiac diabetic range to physicians and diabetologists. Track which products are moving and reorder only those.
- Days 61 to 90: Review chemist-wise sales, cut slow movers from your next order, and add 10 to 15 new doctors. This is also when you can judge if you need a second MR.
Summary: monopoly protects your territory, but only consistent supply and doctor visits protect your prescriptions.
6 Common Mistakes in a Pediatric and Cardiac Diabetic PCD Franchise
Most PCD franchises that fail do not fail because of the market. They fail because of a handful of avoidable decisions in the first year.
- Ordering the catalogue instead of the market. Buying 150 products on day one feels ambitious. It usually ends in expiry returns.
- Treating both segments the same way. Pediatricians want taste, dosing convenience and parent feedback. Diabetologists want consistency and combinations. One pitch does not fit both.
- Choosing on margin alone. A 10% better margin means nothing if the product is out of stock when the doctor is ready to write it.
- Accepting a verbal monopoly. If it is not in the agreement, it does not exist.
- Ignoring compliance. An expired licence, a missing competent person or careless marketing under UCPMP 2024 can stop your business overnight.
- Expecting cardiac diabetic sales in month one. Chronic therapy doctors switch slowly. Partners who quit at month three never see the month-nine payoff.
If I had to pick the one mistake that costs the most, it is number three. In chronic care, a doctor who has a patient come back saying “the medicine wasn’t available” rarely gives your brand a second chance.
Building a Pediatric and Cardiac Diabetic PCD Pharma Franchise That Lasts
Think back to that mother at the chemist counter. She did not care about PCD models or monopoly clauses. She cared about one thing: will the medicine be there when her family needs it?
Build your Pediatric and Cardiac Diabetic PCD Pharma Franchise around that question and you will build something that lasts. Survey your territory, choose a partner who can prove quality and supply, protect your area in writing, and grow one doctor at a time.
If you are a medical representative, stockist or distributor ready to take the next step, reach out to our franchise team for the current pediatric and cardiac diabetic product lists, price lists and monopoly availability in your district.
Frequently Asked Questions
What are the steps to start a Pediatric PCD Pharma Franchise in India?
Register your business and get GST, then apply on Form 19 for a wholesale drug licence in Form 20B and 21B. Next, shortlist a WHO-GMP certified Pediatric PCD Pharma Company, verify its quality records, sign a written monopoly agreement, place a focused opening order of 25 to 40 products and start visiting pediatricians and chemists in your territory.
What is the investment required for a Pediatric PCD Pharma Franchise?
In my experience, a Pediatric PCD Pharma Franchise for one district needs roughly ₹1.5 lakh to ₹3.5 lakh, covering licence fees, premises setup, first stock and three months of working capital. Adding a Cardiac Diabetic range typically takes the total to ₹3 lakh to ₹7 lakh, depending on your city and team size.
Can one company supply both a Pediatric and Cardiac Diabetic PCD franchise?
Yes. Many PCD companies offer both ranges under separate divisions. Working with one company simplifies ordering, credit and monopoly terms. Just confirm in writing that your monopoly covers both divisions and any future launches, and that the company has real depth in each segment.
What should distributors check when choosing a Cardiac Diabetic PCD Pharma Company?
Check WHO-GMP certification and revised Schedule M compliance, the depth of its diabetes, hypertension and cholesterol range, stock availability on the top 50 products, written monopoly rights, a clear expiry policy and references from existing partners. Supply consistency matters most, because chronic patients need refills every month.
What does monopoly rights mean in a PCD Pharma Franchise?
Monopoly rights mean the company will not appoint another franchise partner for the same products in your defined territory. The agreement should name the territory, the divisions and product lists covered, any performance conditions and the terms under which the monopoly can be withdrawn.
Which licences are required for a PCD Pharma Franchise Business in India?
You need GST registration and a wholesale drug licence in Form 20B and Form 21B, issued by your State Drugs Control Department after an inspection. The premises must be at least 10 square metres, with proper storage, a refrigerator and a competent person in charge.
How long does it take for a Cardiac Diabetic PCD Franchise to become profitable?
Pediatric products usually show steady repeat orders within two to three months. Cardiac diabetic medicines take longer, often four to six months, because doctors trial a new brand on a few patients first. Once they switch, chronic prescriptions bring very stable monthly revenue.
About the Author
Aman Goyal is a Designated Partner at Oasis Bio Bloom LLP, where he leads the company’s PCD pharma franchise network, regional expansion and distribution strategy. His expertise spans PCD pharma franchise strategy, pharmaceutical marketing, supply chain and business operations. Backed by a leadership team with 30+ years of collective pharmaceutical industry experience, he helps distributors across India build profitable franchises through reliable supply chains, transparent franchise models and strict quality standards.
Sources
- ICMR-INDIAB study, The Lancet Diabetes & Endocrinology (2023), as reported by ThePrint, M3 India and Scroll
- UNFPA, State of World Population 2025, via Drishti IAS and UNFPA India data
- Drug licence premises rules: Delhi Drugs Control Department; licence fee: Lawrbit
- Revised Schedule M deadline: Business Standard
- Excipient testing after the Coldrif deaths: Business Standard, The Tribune



